Vaxart 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Andy Floroiu

최고 경영자

US$2.4m

총 보상

CEO 급여 비율	19.4%
CEO 임기	2.1yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.1yrs
이사회 평균 재임 기간	1.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Andy Floroiu 의 보수는 Vaxart 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2022	n/a	n/a	-US$80m
Dec 31 2021	US$2m	US$467k	-US$70m
Sep 30 2021	n/a	n/a	-US$64m
Jun 30 2021	n/a	n/a	-US$54m
Mar 31 2021	n/a	n/a	-US$47m
Dec 31 2020	US$3m	US$220k	-US$32m

보상 대 시장: Andy 의 총 보상 ($USD 2.41M )은 German 시장( $USD 1.03M ).

보상과 수익: Andy 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Andy Floroiu (49 yo)

2.1yrs

테뉴어

US$2,410,175

보상

Mr. Cezar Andrei Floroiu, also known as Andy, M.B.A., serves as the Chief Executive Officer at Vaxart, Inc. since June 14, 2020 and served as Principal Financial Officer at Vaxart, Inc. since June 14, 2020...

리더십 팀

이름	위치	테뉴어	보상	소유권
Cezar Floroiu	CEO, President & Director	2.1yrs	US$2.41m	데이터 없음
Sean Tucker	Senior VP & Chief Scientific Officer	12.4yrs	US$1.19m	데이터 없음
James Cummings	Chief Medical Officer	less than a year	US$2.38m	데이터 없음
Fuad Ahmad	Interim CFO and Principal Financial & Accounting Officer	less than a year	데이터 없음	0.0040% € 21.2k
Edward Berg	Senior VP & General Counsel	less than a year	데이터 없음	데이터 없음
Shaily Garg	Senior Vice President of Clinical Development & Project Management	2.3yrs	데이터 없음	데이터 없음
Brant Biehn	Senior Vice President of Business Operations	4.3yrs	데이터 없음	데이터 없음
Rajesh Kapoor	Senior Vice President of Quality	1.5yrs	데이터 없음	데이터 없음
John Harland	Consultant	3.5yrs	US$418.05k	데이터 없음

2.1yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: NB11 의 관리팀은 경험 ( 2.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Cezar Floroiu	CEO, President & Director	2.3yrs	US$2.41m	데이터 없음
Robert Yedid	Lead Independent Director	2.8yrs	US$158.00k	0.0041% € 22.2k
Harry Greenberg	Member of Scientific & Clinical Advisory Board	less than a year	데이터 없음	데이터 없음
Karen Wilson	Independent Director	1.9yrs	US$158.00k	0% € 0
Todd Davis	Independent Chairman of the Board	2.8yrs	US$171.00k	0.094% € 502.7k
Michael Finney	Independent Director	15.5yrs	US$152.40k	0.52% € 2.8m
Stefan Gravenstein	Member of Scientific & Clinical Advisory Board	less than a year	데이터 없음	데이터 없음
David Wheadon	Independent Director	1.3yrs	US$485.94k	0% € 0
Robert Belshe	Member of Scientific & Clinical Advisory Board	less than a year	데이터 없음	데이터 없음
Marion Pepper	Member of Scientific & Clinical Advisory Board	less than a year	데이터 없음	데이터 없음
Ralph Baric	Member of Scientific & Clinical Advisory Board	less than a year	데이터 없음	데이터 없음
Gregory Gray	Member of Scientific & Clinical Advisory Board	less than a year	데이터 없음	데이터 없음

1.1yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: NB11 의 이사회는 경험(평균 재직 기간 1.1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Vaxart 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Vaxart, Inc. Announces Board Changes

Recent updates

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

Vaxart, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Vaxart, Inc. Announces Board Changes

Vaxart, Inc. Appoints W. Mark Watson to Its Board of Directors

Vaxart, Inc. Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

Vaxart, Inc. Announces Management Changes

Margaret Echerd Notifies as Senior Vice President and Principal Accounting Officer of Vaxart, Inc, Effective as of May 5, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Vaxart, Inc. Appoints Edward B. Berg as Senior Vice President and General Counsel

High number of new and inexperienced directors

Forecast to breakeven in 2024

High number of new and inexperienced directors

Forecast to breakeven in 2024

Vaxart to Test Cross-Reactivity of Its Covid-19 Oral Tablet Vaccine Against Omicron

No longer forecast to breakeven

High number of new and inexperienced directors

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령